WNBAs Erica Wheeler Lost Mom To Cervical Cancer, Urges More Screening

Why It Matters

Improving screening rates can close racial gaps and prevent avoidable deaths, while celebrity advocacy amplifies public‑health messaging.

Key Takeaways

• Wheeler partners with Hologic for cervical cancer screening campaign
• Screening reduces U.S. cervical cancer mortality over 70%
• One in four U.S. women not up‑to‑date screening
• Black women screening rates 10% lower than White women
• Black women face 75% higher cervical cancer mortality

Pulse Analysis

The decline in cervical cancer mortality in the United States is one of the most striking successes of preventive medicine. Since the introduction of the Papanicolaou smear in the 1940s, routine screening has lowered death rates by more than 70 percent, a figure confirmed by recent obstetrics and gynecology reviews. Modern protocols combine Pap tests with high‑risk HPV detection, allowing clinicians to intervene before lesions become invasive. As guidelines from the USPSTF and the American Cancer Society recommend three‑year intervals for younger women and five‑year co‑testing after age thirty, the clinical pathway is well established, yet adherence remains uneven.

Disparities in screening uptake reveal systemic inequities that disproportionately affect Black women. A 2023 American Journal of Preventive Medicine analysis of 188,000 patients showed only 53.2 % of Black women were screened within three years, compared with 63.5 % of White women. Contributing factors include limited access to trusted providers, financial barriers, and competing life demands—issues Wheeler herself cited from her mother’s experience as a single parent. By aligning with Hologic, Wheeler brings a high‑visibility platform to these underserved communities, translating personal loss into a call for preventive action.

The partnership between a professional athlete and a diagnostics leader underscores a growing trend of health‑focused influencer campaigns. Hologic’s “Ultimate Defense” leverages Wheeler’s credibility to drive awareness, especially for at‑home HPV testing that can reduce visit‑related obstacles. For insurers and health systems, such advocacy can improve screening rates, lower downstream treatment costs, and narrow the mortality gap. Continued investment in culturally competent outreach, coupled with convenient testing options, will be essential to sustain the gains of past decades and ensure that every woman, regardless of background, receives timely cervical cancer protection.